(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2022 (28.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/087458 A1

(51) International Patent Classification:
A61K 38/20 (2006.01) *A61K 47/68* (2017.01)

(21) International Application Number:
PCT/US2021/056312

(22) International Filing Date:
22 October 2021 (22.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/105,162	23 October 2020 (23.10.2020)	US
63/121,663	04 December 2020 (04.12.2020)	US
63/190,669	19 May 2021 (19.05.2021)	US

(71) Applicant: **ASHER BIOTHERAPEUTICS, INC.** [US/US]; 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US).

(72) Inventors: **YEUNG, Yik Andy**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **DJURETIC, Ivana**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **BESSETTE, Paul**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **CHEN, Wei**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **CHIN, Sherman Michael**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **MOYNIHAN, Kelly Dare**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **NGUYEN, Henry C.**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **NI, Irene**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **PAPPAS, Danielle C.**; c/o Asher Biotherapeutics, Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US). **PARK, Terrence**; c/o Asher Biotherapeutics,

(54) Title: FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR MODULATING IMMUNE CELL FUNCTION




FIG. 8C

(57) Abstract: Provided herein are anti-CD8 antigen binding molecules and fusion polypeptides comprising the CD8 antigen binding molecules for selectively modulating the function of CD8+ T cells over other immune cells. In addition, the present disclosure also provides polynucleotides encoding the disclosed antigen binding molecules and fusion polypeptides, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the antigen binding molecules and fusion polypeptides, pharmaceutical compositions comprising the same, and uses thereof.

WO 2022/087458 A1

[Continued on next page]

Inc., 650 Gateway Blvd., Suite 100, South San Francisco, California 94080 (US).

(74) **Agent: ONUFRYK, Christina** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*